TickerTalks
Browse all tickers →
TickerTalks›$MRVI
MRMRVI

Maravai LifeSciences Holdings, Inc.

$MRVI·$2.1B·Biotechnology·Healthcare
$6.79-4.0%YTD+99.7%1Y+94.6%
Price updated 7h ago·X counts updated 5d ago
MRMRVI
$MRVIMaravai LifeSciences Holdings, Inc.
$6.79-3.96%39 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $MRVI on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

39X posts · last 7 days
Sep 29Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $MRVI's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 77% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-08-28

Maravai LifeSciences posts are cautiously bullish, framing MRVI as a healthcare-space rotation beneficiary with strong entry tactics on catalyst + highest-volume-in-a-year (edge). Sample is thin with some skeptical outsider commentary; overall tone is opportunistic bullish.

Read what X is saying about $MRVI

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $MRVI — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Driven by hypeAcceleratingAI verdict · as of 2026-10-03

The move is getting stronger, with heavier trading behind it.

Maravai up 141% YTD on RNA-consumables flywheel — the post-COVID reset is now the forward growth vector.

Maravai LifeSciences is a specialty-RNA-consumables company (CleanCap technology) whose 2026 breakout reflects the post-COVID reset creating a specific RNA-based-therapeutics growth tailwind rather than COVID-related comparables.

  • The P&L is reaccelerating: Q2 revenue grew 40.5% YoY to $66M at a 3.7% operating margin and EPS of -$0.03, with trailing EPS beats of 54% and 120% — these are the kinds of large surprises typical of a company whose end-market demand is reaccelerating against conservative Street models.
  • The specific capital-markets positioning is substantive: 'The Post-COVID Reset Has Created An RNA Consumables Flywheel' Seeking Alpha framing plus Dimensional Fund Advisors boosting holdings plus the TriLink BioTechnologies CleanCap China patent — three coordinated signals.

At 78% of its 52-week range and 63% above the 200-day going into Nov 5 earnings, the setup is late-cycle hot-momentum. Another 50%+ EPS surprise plus continued CleanCap-adoption commentary is the trigger for continuation; a soft Nucleic Acid Products segment or any specific competitive-signal from Chinese generics is the invalidation.

Agrees with X sentimentThe 'RNA Consumables Flywheel' framing is grounded, and the TriLink Chinese patent plus Dimensional Fund Advisors increase are specific institutional positioning signals.

What to watch: Nov 5 Q3 earnings — Nucleic Acid Products revenue, CleanCap adoption commentary, operating margin direction, and FY27 guide. 50%+ EPS surprise plus CleanCap momentum is the trigger; competitive signal is the invalidation.

On the calendar: 2026-11-05 — Q3 earnings

event ahead 30drna consumables

Read the AI verdict on $MRVI

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Supplies mRNA synthesis inputs (CleanCap), nucleotides, and bioanalytical services critical to mRNA vaccine and therapeutics manufacturing.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $MRVI.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $MRVI

Neutral — Supplies mRNA synthesis inputs (CleanCap), nucleotides, and bioanalytical services critical to mRNA vaccine and therapeutics manufacturing.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-7.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
6.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
21.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-3.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
6.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-44.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
29.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.02$-0.04+54.1%
Q1 2026May 7, 2026$0.01$-0.05+120.0%
Q4 2025Feb 25, 2026$-0.04$-0.07+42.9%
Q3 2025Nov 6, 2025$-0.08$-0.06-33.3%
Next earningsWed, Nov 4·consensus EPS $-0.06

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$65.8M+40.5%51.2%3.8%$-0.03$4.2M
Q4 FY25$49.9M-11.6%24.5%-13.5%$-0.25$-24.9M
Q3 FY25$41.6M-36.2%13.6%277%$-0.18$-18.1M
Q2 FY25$47.4M-35.4%16.4%-140%$-0.27$-13.1M

Forward consensus

5-year forecast · up to 7 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$211.8M$210.8M – $213.4M-$0.11-$0.15 – -$0.087
FY27$224.9M$221.2M – $229.1M-$0.10-$0.23 – -$0.027
FY28$240.5M$232.1M – $250.2M-$0.07-$0.08 – -$0.065
FY29$256.1M$251.4M – $260.7M-$0.09-$0.09 – -$0.092
FY30$276.1M$270.9M – $280.9M-$0.06-$0.06 – -$0.062

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.62%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-5.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+34.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 106.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.605-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 10Kurt OreshackGeneral Counsel25.0K sh$127KSellJun 9Kurt OreshackGeneral Counsel25.0K sh$126K
+ 19 other (9 inkinds · 9 awards · 1 gift) in window

See when $MRVI insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KAgreement terminatedJun 38-K — Item 1.01: Material agreement · Item 1.02: Agreement terminated · Item 2.03: Material debt obligation · Item 7.01: Press release / Reg FD
AI summary

Maravai LifeSciences Holdings, Inc. (MRVI) disclosed a material definitive agreement under Item 1.01, reporting a merger or acquisition transaction involving growth company as defined in Rule. The deal is valued at approximately $150.0 million. Details of the transaction terms, consideration structure, and closing conditions are set forth in the full 8-K filing. Definitive merger agreements are among the most material events a public company can disclose, triggering regulatory review and shareholder vote requirements.

8-KShareholder voteMay 298-K — Item 5.07: Shareholder vote
AI summary

Maravai LifeSciences Holdings held its 2026 Annual Meeting on May 26, 2026, with 236M of 258M total shares present. Shareholders elected three directors (Bernd Brust, Gregory Lucier, Luke Marker) to three-year terms expiring at the 2029 Annual Meeting; Deloitte & Touche was ratified as auditor for 2026 (234M For, 1.2M Against); and a say-on-pay advisory vote was also conducted. Routine annual governance; no contested items.

+ 14 other (7 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026businesswire.com·3d agoMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stock Has Average Price Target of $6.83defenseworld.net·12d agoTriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IPbusinesswire.com·18d agoMaravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables Flywheelseekingalpha.com·45d agoDimensional Fund Advisors LP Boosts Holdings in Maravai LifeSciences Holdings, Inc. $MRVIdefenseworld.net·65d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPR

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · last 7 days

No standout posts about $MRVI on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport